Showing results (11-20 of 41) with videos related to
Sort By:
Pageof 5
Frontiers in Pharmacology|July 19, 2021
High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19Mario Karolyi, Sara Omid, Erich Pawelka, et al.American Journal of Infection Control|October 31, 2021
Evaluation of RT-qPCR of mouthwash and buccal swabs for detection of SARS-CoV-2 in children and adultsHermann Laferl, Tamara Seitz, Sebastian Baier-Grabner, et al.Wiener Klinische Wochenschrift|September 14, 2017
Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy : Final results of the Austrian PegHope studyMichael Gschwantler, Hermann Laferl, Wolfgang Vogel, et al.Wiener Klinische Wochenschrift|September 7, 2022
Comparison of clinical characteristics among patients infected with alpha vs. delta SARS-CoV-2 variantsBenedikt Rumpf, Benno Lickefett, Clemens Baumgartner, et al.Hepatology (Baltimore, Md.)|October 19, 2011
Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirinThomas-Matthias Scherzer, Albert Friedrich Stättermayer, Michael Strasser, et al.SN Comprehensive Clinical Medicine|January 11, 2021
Clinical and Angiographic Features in Three COVID-19 Patients with Takotsubo Cardiomyopathy. Case ReportWolfgang Hoepler, Marianna Theresia Traugott, Guenter Christ, et al.Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|February 18, 2006
Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary infection and reinfectionJudith H Aberle, Elisabeth Formann, Petra Steindl-Munda, et al.Journal of Hepatology|December 13, 2005
Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infectionPeter Ferenci, Elisabeth Formann, Hermann Laferl, et al.Journal of Hepatology|July 16, 2013
Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patientsThomas-Matthias Scherzer, Albert Friedrich Stättermayer, Rudolf Stauber, et al.Gastroenterology|May 28, 2008
Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological responsePeter Ferenci, Hermann Laferl, Thomas-Matthias Scherzer, et al.Pageof 5